SEC Form 6-K filed by Molecular Data Inc.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2021

 

Commission File Number: 001-39167

 

Molecular Data Inc.

 

11/F, Building 15, 2177 Shenkun Road

Minhang District, Shanghai 201106

People’s Republic of China
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒              Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

Explanatory Note

 

On November 26, 2021, Molecular Data Inc. submitted herewith an interim balance sheet as of the end of its third quarter.

 

Financial Statements and Exhibits.

 

Exhibit No.		Description
99.1		Interim Balance Sheet as of September 30, 2021

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Molecular Data Inc.
	By :	/s/ Steven Foo
	Name :	Steven Foo
	Title :	Chief Executive Officer and Chief Financial Officer

 

Date: November 26, 2021

 

 

Exhibit 99.1

 

CONSOLIDATED STATEMENTS OF BALANCE SHEET

 

(Amounts in thousands of RMB and US$,

except for number of shares and per share data)

 

		As of December 31, 2020				As of September 30, 2021
		(RMB’000)				(RMB’000) unaudited				(USD’000)
Assets
Current assets:
Cash and cash equivalents			11,311				66,339				10,296
Restricted cash			277				—				—
Accounts receivable, net			5,963				6,211				964
Short-term investments			336,038				336,038				52,152
Unbilled receivables			51,825				56,842				8,822
Notes receivable			24,761				22,539				3,498
Inventories, net			2,821				5,784				898
Amounts due from related parties			1,144				7,178				1,114
Prepayments and other current assets			229,046				229,999				35,696
Total current assets			663,186				730,930				113,440
Non-current assets:
Long-term investment			353				3,753				582
Property and equipment, net			725				469				73
Intangible assets, net			536				372				58
Deferred assets & deferred tax assets			15,826				7,773				1,206
Right-of-use asset, net			4,195				2,796				434
Total non current assets			21,635				15,163				2,353
Total assets			684,821				746,093				115,793
Liabilities and Shareholders’ Equity
Current liabilities:
Short-term borrowings			33,749				16,149				2,506
Accounts payable			315,729				313,196				48,607
Deferred revenue			81,636				66,429				10,310
Accrued expenses and other liabilities			132,674				106,506				16,532
Convertible notes			16,096				39,453				6,123
Amounts due to related parties			111,186				119,531				18,551
Operating lease liabilities-current			1,536				1,393				216
Total current liabilities			692,606				662,657				102,845
Non-current liabilities:
Non-current portion of capital lease obligations			17,052				17,052				2,646
Non-current portion of lease liability			2,659				1,403				218
Contingency liability			341				341				53
Total non-current liabilities			20,052				18,796				2,917
Total liabilities			712,658				681,453				105,762
Redeemable noncontrolling interests			42				—				—
Shareholders’ equity/(deficit)
Ordinary shares			114				202				31
Additional paid-in capital			1,075,064				1,231,970				191,199
Accumulated other comprehensive loss			(21,192	)			(21,192	)			(3,289	)
Accumulated deficit			(1,081,914	)			(1,146,669	)			(177,961	)
Total shareholders’			(27,928	)			64,311				9,980
Non-controlling interest			49				329				51
TOTAL (DEFICIT)/EQUITY			(27,879	)			64,640				10,031
Total liabilities and shareholders’ (deficit)/ equity			684,821				746,093				115,793